Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
A phase 2 trial of Mirdametinib in Chronic lymphocytic leukaemia, run by National Cancer Institute (NCI), now recruiting.
Overview
Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia is a phase 2 interventional study registered as NCT07061951 by National Cancer Institute (NCI), with 20 participants planned, started 2026-05-27 and due to reach its primary completion in 2030-02-01. Interventions recorded: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Echocardiography Test, Mirdametinib. Conditions recorded: Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma.
Linked to the drug Mirdametinib because the registry names it among its interventions and Chronic lymphocytic leukaemia among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialMirdametinib in Patients With Advanced NF1-mutant Melanoma
Shares Mirdametinib and the tag pipeline.
- TrialMirdametinib in Histiocytic Disorders
Shares Mirdametinib and the tag pipeline.
- TrialA Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies
Shares Chronic lymphocytic leukaemia and the tag pipeline.
- TrialA Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies
Shares Chronic lymphocytic leukaemia and the tag pipeline.
- TrialStudy of APG-2575 in Patients With Relapsed/Refractory CLL/SLL
Shares Chronic lymphocytic leukaemia and the tag pipeline.
- TrialStudy to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)
Shares Chronic lymphocytic leukaemia and the tag pipeline.
- TrialA Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL
Shares Chronic lymphocytic leukaemia and the tag pipeline.
- TrialAcalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL
Shares Chronic lymphocytic leukaemia and the tag pipeline.